Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Springworks Therapeutics (SWTX)
NASDAQ:SWTX
RESEARCH TOOLSreports
Holding SWTX?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.67Last Year’s EPS
-1.44Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 12, 2020
|% Change Since: 3.31%
|Next Earnings Date:Nov 12, 2019
Earnings Call Sentiment|Positive
The earnings call displayed a strong performance for OGSIVEO with significant revenue growth and positive market trends. Expansion efforts into Europe and the promising outlook for mirdametinib contribute to a positive sentiment. However, challenges with the blister pack transition and summer seasonality were noted as short-term hurdles.Company Guidance
During the third quarter of 2024 earnings call for SpringWorks Therapeutics, several key metrics were discussed regarding the company's performance and future outlook. Notably, OGSIVEO, a treatment for desmoid tumors, generated $49.3 million in net product revenue, marking a 23% growth quarter-over-quarter. The enthusiasm for OGSIVEO was evident in the increasing demand from both new and existing patients, with over 800 unique patients filling prescriptions in September. The company introduced 150-milligram and 100-milligram strength tablets in blister packaging, which improved patient adherence and convenience. Additionally, the ICD-10 data indicated a desmoid tumor patient population larger than initially estimated, with 10,000 unique patients identified in the U.S. using the new diagnosis code. The company is also preparing for the potential FDA approval of mirdametinib for NF1-PN by its February 28, 2025, PDUFA date, aiming to serve an estimated 40,000 patients in the U.S. These metrics underscore SpringWorks' strong commercial execution and set the stage for continued growth in the upcoming quarters.Strong Revenue Growth for OGSIVEO
Generated $49.3 million in net product revenue in Q3, representing a 23% growth quarter-over-quarter, driven by robust demand in the U.S. market.
Positive Market Trends and Physician Adoption
High enthusiasm for OGSIVEO with 90% of prescribers likely to use it as a frontline treatment. 65% of patients transitioned to new blister packs, improving adherence.
Significant Opportunity with Mirdametinib
NDA for mirdametinib granted priority review with a potential for approval in early 2025. Strong efficacy and safety profile reported in pivotal trials.
Expansion into European Markets
EU regulatory reviews for OGSIVEO and mirdametinib underway with anticipated approvals in 2025. European headquarters established and commercial leadership onboarded.
Robust Financial Position
Strong balance sheet with $498 million in cash and marketable securities, expected to fund operations through profitability by the first half of 2026.
---
SWTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SWTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $33.52 | $33.10 | -1.25% |
| Aug 07, 2024 | $33.22 | $33.93 | +2.14% |
| May 02, 2024 | $46.84 | $43.35 | -7.45% |
| Feb 27, 2024 | $48.48 | $52.07 | +7.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Springworks Therapeutics (SWTX) report earnings?
Springworks Therapeutics (SWTX) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Springworks Therapeutics (SWTX) earnings time?
Springworks Therapeutics (SWTX) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SWTX EPS forecast?
SWTX EPS forecast for the fiscal quarter 2024 (Q4) is -0.67.
---